This is great news as the ESMO has had insight into the details of the Phase III (Yondelis for Ovarian Cancer), (which during August,
Zeltia announced was positive, yet without further detail),
and apparently considered the data to be sufficiently significant to justify Yondelis to head a Presidential Symposium at the ESMO (Stockholm Sept 12-16).